Winston Gao - Maple Leaf VP Director
| MGWFF Stock | USD 0.03 0.0009 2.73% |
Insider
Winston Gao is VP Director of Maple Leaf Green
| Phone | 403-452-4552 |
| Web | https://www.mlgreenworld.com |
Maple Leaf Management Efficiency
The company has return on total asset (ROA) of (1.0546) % which means that it has lost $1.0546 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2684) %, meaning that it generated substantial loss on money invested by shareholders. Maple Leaf's management efficiency ratios could be used to measure how well Maple Leaf manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dominic Cundari | DiaMedica Therapeutics | 73 | |
| Antony CPA | Forte Biosciences | 57 | |
| MD MBA | Rezolute | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Edward Calamai | DiaMedica Therapeutics | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Anne Moon | Tempest Therapeutics | N/A | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| Steven Ruhl | Forte Biosciences | 67 | |
| LLM JD | Rezolute | 63 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
| Christopher Roenfeldt | Forte Biosciences | N/A | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| Scott CA | DiaMedica Therapeutics | 59 | |
| Daniel Ryweck | Silo Pharma | 59 | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Joseph Hazelton | Dyadic International | 48 | |
| Robyn Sweinhart | Rezolute | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
Management Performance
| Return On Equity | -0.27 | |||
| Return On Asset | -1.05 |
Maple Leaf Green Leadership Team
Elected by the shareholders, the Maple Leaf's board of directors comprises two types of representatives: Maple Leaf inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Maple. The board's role is to monitor Maple Leaf's management team and ensure that shareholders' interests are well served. Maple Leaf's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Maple Leaf's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Winston Gao, VP Director | ||
| CMA BCom, CEO Chairman | ||
| RPA PBA, CFO, Officer | ||
| Jeffrey Stein, Chief Officer |
Maple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Maple Leaf a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | |||
| Return On Asset | -1.05 | |||
| Current Valuation | 3.04 M | |||
| Shares Outstanding | 33.14 M | |||
| Shares Owned By Insiders | 12.34 % | |||
| Price To Earning | (40.23) X | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 910.73 X | |||
| Revenue | (191.05 K) | |||
| Gross Profit | 1.1 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Maple Pink Sheet
Maple Leaf financial ratios help investors to determine whether Maple Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Maple with respect to the benefits of owning Maple Leaf security.